Protocol Ledger

NCT03439514 · Phase III · TERMINATED

A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation

Interventional Phase III clinical trial protocol NCT03439514 sponsored by Pfizer in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-04-17 Enrollment: 77 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03439514
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)77 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03439514
Protocol FieldVerified Registry Value
NCT IdentifierNCT03439514
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment77 participants (ACTUAL)
Registered Start Date2018-04-17
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03439514
Hospital Research SiteLocationSite Profile
Banner University Medical Center - TucsonTucson, AZOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI